Cuban cancer vaccine will be evaluated by the Roswell Park Cancer Institute
The Cimavax vaccine has been investigated in Cuba for 25 years and is available for free for Cuban patients since 2011. It is produced by the Center of Molecular Immunology.
Last September this institution signed an agreement with the Roswell Park Cancer Institute in Buffalo, New York, to import Cimavax and start performing clinical trials in the United States.
"We are still in the early stages of evaluating the promise of this vaccine, but the evidence so far from clinical trials in Cuba and Europe has been amazing," told The Huffington Post Dr. Kelvin Lee, the Jacobs Family Chair of Immunology and co-leader of the Tumor Immunology and Immunotherapy Program at Roswell Park.
So far, 5000 patients worldwide have been treated with Cimavax, including 1000 patients in Cuba. Lee said the latest Cuban study of 405 patients, which has not yet been published, confirms previous conclusions on the safety and efficacy of the vaccine. And studies have found no significant side effects.